LTRN News & Events

Lantern Pharma announced that it has received a successful response to its recent Type C meeting request from the U.S. Food and Drug Administration, FDA, focused on the ongoing Phase 2 Harmonic trial of LP-300 in never-smokers with advanced non-small cell lung cancer, NSCLC, adenocarcinoma. In its written responses to Lantern's Type C meeting request, the FDA raised no objections to key proposed protocol amendments, providing a more focused, clearer regulatory path forward for the Harmonic trial and for the future development of LP-300 in this distinct, high-need patient population. "In our view, this successful Type C interaction with the FDA is a meaningful de-risking milestone for the LP-300 program and for the Harmonic trial. The FDA's response to our proposed amendments supports our strategy to focus Harmonic on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer meaningful differentiated benefit when added to standard chemotherapy following TKI failure."

Lantern Pharma entered into a definitive agreement for the purchase and sale of an aggregate of 2,135,923 shares of its common stock at a purchase price of $2.06 per share in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,135,923 shares of common stock. The warrants will have an exercise price of $2.27 per share, will be exercisable six months following the initial issuance date, and will expire five years following the initial exercise date. The closing of the offering is expected to occur on or about May 14, 2026, subject to the satisfaction of customary closing conditions. The Company has also communicated plans to create an independent business entity composed of the AI platform, withZeta.ai, and related technologies and personnel under the leadership of CEO Mr. Panna Sharma. The Company intends to separate its public facing clinically trained AI agent into an independent business entity in order to access dedicated funding sources and potentially realize valuation multiples separate from its drug development operations, which such entity the Company anticipates will become a newly listed company on a national stock exchange or market. The Company plans on hosting a separate investor webinar and meeting to provide additional details in the coming month. Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering.

Lantern Pharma unveiled the next phase of its development roadmap for withZeta.ai, the company's multi-agentic A.I. co-scientist platform for oncology research and drug discovery. Future development plans for release in the coming year include three major capability tracks: ZetaSwarm, an autonomous multi-agent swarm intelligence layer; ZetaOmics, a real-time computational biology and multi-omic analytics toolkit that extends withZeta.ai's existing production foundation of 34 bioinformatics, chemoinformatic, and clinical research tools; and a new suite of enterprise-grade platform features designed for institutional and commercial deployment. The roadmap brings together two threads that have been advancing in parallel across AI for biomedicine into a single, integrated research environment. ZetaSwarm and ZetaOmics are intended to make withZeta.ai one of the few platforms in oncology AI that operates fluently in both domains, with shared infrastructure, shared authentication, and a unified audit trail. With ZetaSwarm, ZetaOmics, and enterprise capabilities, withZeta.ai is expected to deepen its role as both a hyper-productivity layer for Lantern's internal R&D focused on novel drug development and as a standalone commercial AI platform offering for the broader oncology research community.

Lantern Pharma announced the expansion of predictBBB.ai into a Large Quantitative Model- a real-time quantitative intelligence engine now accessible to any researcher or drug development team, anywhere in the world, through a single browser interface. The company said, "For the first time, pharmaceutical scientists and medicinal chemists can access a unified, benchmark-validated LQM - not as a batch software installation, not as a siloed cheminformatics tool - but as an on-demand molecular intelligence engine delivered as a web service. By submitting a single SMILES string, users receive a comprehensive, 360-degree developability profile of any small molecule in seconds: a capability that previously required hours of computation across multiple platforms and specialized bioinformatics personnel to integrate - removing the computational barriers that have historically limited rigorous molecular characterization to large, well-resourced pharmaceutical organizations, and making that same analytical power available to biotech innovators, academic drug hunters, and rare disease programs worldwide."